Figure 5
TRF2 represses p21 activation upon cellular DNA damage. (A–C) Treatment with either Doxorubicin or Topotecan was done in HT1080 (A), *p value < 0.05, Student’s t-test; data represented as mean ± SEM of three replicates), MDA-MB-231 (B), data represented as mean ± SEM, for three replicates) and HCT116 p53−/− (C), data represented as mean ± SEM, for three replicates) cells following over-expression of TRF2: loss in p21 activation relative to control vector transformed cells was observed in each case (GAPDH used as internal control for real-time PCR). (D) Quantitative ChIP result shows partial loss of TRF2 occupancy at p21 promoter after doxorubicin treatment in HT1080 cell line.
